Celgene Announces Acceptance of Late Breaking GED-0301 CD-001 Abstract at the United European Gastroenterology Week (UEGW) Me...
October 04 2016 - 7:30AM
Business Wire
Celgene to hold an analyst call on October 18,
2016 at 9 a.m. ET
Celgene Corporation (NASDAQ:CELG) today announced that the data
from a randomized, double-blind, multicenter, exploratory phase Ib
study evaluating the effects of oral GED-0301 (mongersen) on both
endoscopic and clinical outcomes in patients with active Crohn's
disease were accepted as a late breaking abstract at the United
European Gastroenterology Week. The data are to be presented on
October 18, 2016 at 6:27 a.m. ET.
Celgene will hold a conference call for the investment community
to discuss the data on October 18, 2016, at 9 a.m. ET. The
conference call will be available by webcast at www.celgene.com. An
audio replay of the call will be available from noon ET October 18,
2016, until midnight ET October 25, 2016. To access the replay in
the U.S., dial (855) 859-2056; outside the U.S. dial (404)
537-3406. The participant passcode is 87802096.
GED-0301 (mongersen) is an investigational compound that is not
approved for any use in any country.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow Celgene
on Social Media: @Celgene, Pinterest, LinkedIn, FaceBook and
YouTube.
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with the Securities
and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161004005447/en/
Celgene CorporationPatrick E. Flanigan III,
908-673-9969Corporate VP, Investor RelationsorBrian Gill,
908-673-9530VP, Corporate Communications
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024